← Leaderboards
Katherine Renee Amato Hastings
Vanderbilt University
$192,977
Attributed
$192,977
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $59K · FY2012–18$100K$75K$50K$25K$0
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$192,977 · 2
By mechanism
F32$115,732 · 1
F31$77,245 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Pierre P Massion$18,568,000
- Ann Richmond$15,857,391
- Dana M Brantley-Sieders$4,304,141
- John Tanner Wilson$7,006,172
- Robert J Coffey$53,530,293
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceUnited StatesKras2 GeneRefractorySignal TransductionTreatment StrategyGenerationsIn VivoMolecularOncogenicEpidermal Growth Factor ReceptorCancer EtiologySurvival RateCancer PatientDrug ResistanceChronicGeneticInvestigationLung NeoplasmsMalignant Neoplasm Of LungMouse ModelMutationCessation Of LifeAblation
Grant awards (5)
Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Lung Adenocarcinoma$59,038
F32 · FY2018 · CA · contact PI
Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Lung Adenocarcinoma$56,694
F32 · FY2017 · CA · contact PI
Targeting EphA2 in Tyrosine Kinase Inhibitor Resistant Lung Cancer$23,547
F31 · FY2014 · CA · contact PI
Targeting EphA2 in Tyrosine Kinase Inhibitor Resistant Lung Cancer$26,849
F31 · FY2013 · CA · contact PI
Targeting EphA2 in Tyrosine Kinase Inhibitor Resistant Lung Cancer$26,849
F31 · FY2012 · CA · contact PI